Exposing EMA secrets
This article was originally published in Scrip
Yet again the European Medicines Agency has become embroiled in a fracas about the apparently careless way it allows its senior executives to move from the agency to the private sector. The EMA's top lawyer, Vincenzo Salvatore had his leaving party at EMA on June 15 and a week later he again uncorked the champagne again at the US law firm, Sidley Austin, where he was to head up the European life sciences regulatory practice.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.